E Pure-Play Psychedelic Stocks Index Continued To Decline Wednesday For 4th Straight Day

TM Editors Note: Many of the companies mentioned in this article are penny stocks and/or microcaps. Such stocks are readily manipulated; do your own careful due diligence.

This article tracks the performance of 15 of the 31 biopharmaceutical companies involved in the research and development of psychedelic compounds to treat mental health issues such as obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, anxiety, and eating disorders in the munKNEE Pure-Play Psychedelic Stocks Index.

Index Inclusion Criteria

The 15 stocks eligible for inclusion in the index are based on the following criteria:

  • a market capitalization between US$10M and US$200M
  • a stock that trades between US$0.10/share and US$2/share

Below are the 15 eligible companies in the munKNEE Pure-Play Psychedelic Stocks Index and their performance on Wednesday, December 30th in alphabetical order. Yesterday's performance for each is in brackets.

  1. Better Plant (VEGGF-32.8% (-11.2%)
  2. Champignon (SHRMF) -5.6% (-6.3%)
  3. Cybin (CLXPF) -0.7% (+0.7%)
  4. Havn (HAVLF) -6.8% (+8.3%)
  5. Hollister (HSTRF) -5.0% (N/C)
  6. Jaguar (JAGX) -3.8% (-4.6%)
  7. Mind Cure (MCURF-3.9% (-8.4%)
  8. Mydecine (MYCOF) N/C (-8.6%)
  9. Nova Mentis (LIBFF) +5.9% (-16.5%)
  10. Numinus (LKYSF) -14.6% (N/C)
  11. Psyched Wellness (DCNPF) +5.0% (-11.4%)
  12. Red Light (TRUFF) +5.4% (-17.2%)
  13. Revive (RVVTF-7.1% (-7.4%)
  14. Seelos (SEEL) +6.2% (-15.1%)
  15. Silo Pharma (SILO) N/C (+10.3%)

The average performance of the above 15 psychedelic drug stocks Wednesday was -2.2% vs. -6.4% on Tuesday. To avoid duplication please refer to a previous article (see here) in which I provided introductory paragraphs on each of the above constituents.

NOTE: The 3 largest psychedelic drug stocks in the sector were down -5.3% on Wednesday vs. -3.1% Tuesday and -2.8%, on average, on Monday. They are not included in the Index because they either trade in excess of $2/share and/or have a market cap in excess of $200M, since their inclusions would make a comparative analysis and Index averages meaningless. For the record, below are their Wednesday performances with Tuesday's performances in brackets:

1 2
View single page >> |

Visit  munKNEE.com and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.